

AMENDMENTS TO THE CLAIMS

1. - 20. (Cancelled)

21. (Original) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:5 or 7.

22. (Original) The purified polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:5.

23. (Original) The purified polypeptide of claim 22, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:7.

24. - 26. (Cancelled)

27. (Original) A purified polypeptide comprising amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 or 23-36, 52-58, and 91-101 of SEQ ID NO:7.

28. (Original) The purified polypeptide of claim 27, wherein said polypeptide comprises amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5.

29. (Original) The purified polypeptide of claim 27, wherein said polypeptide comprises amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7.

30. (Currently Amended) The purified polypeptide of ~~any one of claims 18-29~~  
claim 21 or claim 27 wherein said polypeptide is an antibody or a functional fragment thereof.

31. (Original) The purified polypeptide of claim 30, wherein said antibody is a monoclonal antibody or a functional fragment thereof.

32. (Original) The purified polypeptide of claim 30, wherein said functional fragment is selected from the group consisting of  $V_L$ ,  $V_H$ ,  $F_v$ ,  $F_C$ ,  $Fab$ ,  $Fab'$ , and  $F(ab')_2$ .

33. (Original) The purified polypeptide of claim 30, wherein said polypeptide specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, and an adenocarcinoma of the lung, and not to non-neoplastic cells of the same tissue type.

34. (Cancelled)

35. (Original) A functional fragment of an antibody, wherein said functional fragment comprises amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 or 23-36, 52-58, and 91-101 of SEQ ID NO:7.

36. (Currently Amended) The functional fragment of claim 34 or 35, wherein said functional fragment is a functional fragment of a monoclonal antibody.

37. (Currently Amended) The functional fragment of claim 34 or 35, wherein said functional fragment is a V<sub>L</sub> chain of an antibody.

38. - 41. (Cancelled)

42. (Original) A purified polypeptide that specifically binds to a neoplastic cell, but does not bind to a non-neoplastic cell, wherein said purified polypeptide specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, and an adenocarcinoma of the lung, and not to non-neoplastic cells of the same tissue type, and wherein said purified polypeptide is substantially identical to the full-length sequence of SEQ ID NO:5 or SEQ ID NO:7.

43. (Original) The purified polypeptide of claim 42, wherein said polypeptide specifically binds to at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM1604 (DSMZ Accession Number ACC 298) cells.

44. (Original) The purified polypeptide of claim 43, wherein said polypeptide induces apoptosis in said neoplastic cell, but does not induce apoptosis in said non-neoplastic cell.

45. (Original) The purified polypeptide of claim 43, wherein said polypeptide decreases proliferation of said neoplastic cell, but does not decrease proliferation of said non-neoplastic cell.

46. (Cancelled)

47. (Currently Amended) The purified polypeptide of any one of ~~claims 21-23, 27-29, 35-37, and 42-45~~ claims 21, 27, or 42, wherein said polypeptide is also produced by the NORM-2 cell line having DSMZ deposit accession number DSM ACC2626.

48. - 88. (Cancelled)